Võrdle meetodeid

	Bayesian Microbiome Diversity Analysis	Bayesian Metaboloomika Analüüs
Valdkond	Bioinformaatika	Bioinformaatika
Perekond	Process / pipeline	Process / pipeline
Tekkeaasta	2010s (Dirichlet-Multinomial approach formalized ~2012; extensions ongoing)	2005–2010
Looja	Ian Holmes, Katie Harris, Christopher Quince (Dirichlet-Multinomial Mixture framework, 2012); broader Bayesian microbiome modeling community	Simon Rogers, Mark Girolami and colleagues (Bayesian NMR metabolomics framework, ~2009); broader Bayesian metabolomics developed through 2000s–2010s
Tüüp	Probabilistic/Bayesian pipeline for compositional count data	Probabilistic statistical pipeline
Algallikas	Holmes, I., Harris, K., & Quince, C. (2012). Dirichlet Multinomial Mixtures: Generative Models for Microbial Metagenomics. PLOS ONE, 7(2), e30126.	Rogers, S., Scheltema, R. A., & Girolami, M. A. (2009). Bayesian analysis of metabolomic NMR data. Bioinformatics, 25(14), 1809-1815.
Rööpnimetused	Bayesian microbiome profiling, Dirichlet-Multinomial microbiome analysis, Bayesian alpha/beta diversity, probabilistic microbiome diversity	Bayesian metabolomics, probabilistic metabolomics, Bayesian metabolite profiling, Bayesian metabolic flux analysis
Seotud	5	6
Kokkuvõte	Bayesian microbiome diversity analysis applies probabilistic models — chiefly Dirichlet-Multinomial and related hierarchical frameworks — to 16S rRNA or shotgun metagenomic count data to estimate alpha-diversity (within-sample richness and evenness) and beta-diversity (between-sample compositional differences) while propagating uncertainty through the entire inference chain. Unlike frequentist rarefaction-based approaches, Bayesian methods treat taxon counts as draws from a latent composition, enabling credible intervals on diversity metrics and principled comparison across groups with unequal sequencing depth.	Bayesian metabolomics analysis applies probabilistic inference to metabolite abundance data — typically from mass spectrometry or NMR spectroscopy — to identify differentially abundant metabolites, annotate spectral features, and integrate pathway knowledge. By encoding prior biological knowledge into prior distributions and propagating uncertainty throughout the analysis, it yields more calibrated probability statements about metabolic differences than classical frequentist testing alone.